Interim report
Page 1
1 | OSSDSIGN AB | info@ossdsign.com | ossdsign.com January – June 2026 2026 Interim Report for the second quarter
Page 2
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 2 Interim Report for the second quarter of 2026 January 1 – June 30, 2026 The second quarter in figures • Net sales amounted to TSEK 37,776 (46,522), which translates to a flat growth quarter-over-quarter with constant exchange rates, or 2.4% growth in reported figures. This is in line with expectations and our market guidance. • Gross margin of 92.1% is an improvement over the 91.6% in the first quarter of 2026 but below the 96.8% in the second quarter of the previous year, negatively affected by product and customer mix. • Reported EBIT of TSEK -12,348 (-6,936). • Adjusted EBIT of TSEK -11,975 (-6,203), with the reduction in sales variable costs making up for some of the gross profit shortfall. • Operating expenses were lower than last year with non-sales variable costs being level with last year. Sales variable costs were down to 44.8% (48.6%) of net sales in the period. • Net result for the period amounted to TSEK -11,408 (-8,340). • Earnings per share of SEK -0.1 (-0.1). • Cash flow from operating activities of TSEK –11,811 (-11,895), level with last year due to the positive working capital development. The first half year in figures • Net sales amounted to TSEK 74,655 (91,016), which translates to a decrease of 10% with constant exchange rates, or 18% in reported figures. The significant divergence in growth rates is entirely attributable to the exchange rate depreciation of the USD relative to the SEK, from 10.2 to 9.2, during the comparison periods. Financial overview • Gross margin of 91.9% (96.6%). The margin was negatively affected by product and customer mix. • Reported EBIT of TSEK -25,813 (-19,633). • Adjusted EBIT of TSEK -25,363 (-11,766), as a direct consequence of the lower sales and gross margin, with some mitigation from lower operating expenses. • Operating expenses were lower than last year and sales commissions and fees were down to to 45.9% (49.0%) of net sales in the period. • Net result for the period amounted to TSEK -22,882 (-22,917). • Earnings per share of SEK -0.2 (-0.2). • Cash flow from operating activities of TSEK -26,677 (-37,769), primarily due to the favourable working capital development in the first half of 2026. Significant events during the second quarter • OssDsign Catalyst® outperforms earlier-generation bone graft as a standalone treatment in trauma study. • OssDsign appoints Adam McCollister as new Vice President of Sales. Significant events after the end of the second quarter • There were no significant events after the end of the second quarter. 2026 2025 2026 2025 2025 The group Apr 1 – Jun 30 Apr 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Dec 31 Net sales, TSEK 37 776 46 522 74 655 91 016 180 159 Adjusted operating result, TSEK -11 975 -6 203 -25 363 -11 766 -26 499 Operating result, TSEK -12 348 -6 936 -25 813 -19 633 -46 757 Result for the period, TSEK -11 408 -8 340 -22 883 -22 917 -50 988 Equity ratio, % 78% 80% 78% 80% 77% Earnings per share, SEK -0.1 -0.1 -0.2 -0.2 -0.5 Average number of employees 36.6 32.0 35.0 31.7 32.0
Page 3
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 3 CEO Statement We are building the right team. We are expanding our evidence. All of this supports OssDsign’s goals of driving growth and solid business performance every quarter. Progress: Building the foundation for OssDsign growth During the second quarter, we continued to reshape our sales organization while strengthening our commercial strategy to position OssDsign for its next phase of growth. On June 25, we announced the appointment of a new Vice President of Sales in the US, who brings years of experience in orthopaedic sales and commercial leadership. We have replaced more than 50% of OssDsign’s sales team, adding new colleagues continuously throughout the year within a more rigorous hiring process. As noted in prior statements, these foundational changes began at the start of this year. While we don’t usually provide specific quarterly sales guidance, we continue to work on transparency to establish trust and credibility with our shareholders. Although we expect to see the usual US vacations seasonality in July and August weigh on our Q3 results, we still have confidence that our work will translate into tangible results later this year. Revenue for April through June 2026 totaled USD 4 million, or SEK 37.8 million, essentially flat versus first quarter results and in line with our second quarter guidance. Year over year, revenue growth was -16% (-19% in SEK), against a prior year comparison quarter that benefited from some late-arriving large orders. Adjusted EBIT for the quarter was SEK -12.0 million, an improvement of SEK 1.4 million versus the first quarter. Gross margin for the quarter was 92.1%, an improvement over 91.6% in Q1 2026 but still below the 96.8% achieved in Q2 last year, primarily reflecting product and customer mix impact. As I’ve discussed in prior releases this year, the slowdown we experienced in Q4 2025 and Q1 2026 was driven by several factors, including a slower pace of sales hiring, elevated but expected turnover within the sales team, and reduced activity from certain key accounts undergoing contract renegotiations. These same dynamics continued to affect OssDsign’s second quarter results, although we’ve made progress across all three areas. While I would have preferred stronger growth in Q2, I’m encouraged by the leading indicators we are seeing, both in OssDsign’s quarter-over-quarter trajectory and in the work being done to strengthen the company’s foundations for a return to growth. Returning OssDsign to a strong growth trajectory remains our top priority, and we are pursuing that objective with speed and disciplined capital allocation. With new leadership in place, and continued preclinical and clinical evidence that support Catalyst’s performance, I’m confident we’re executing the strategy and building the team that will drive our turnaround. We will continue to increase the overall size of our sales team, adding more colleagues ahead. Our shareholders have placed their capital and trust in this team to grow, and OssDsign’s responsibility is clear: to deliver growth through strong execution, a best-in-class product, and unwavering integrity. The management team is fully aligned with that mission, and since February, our entire commercial incentive structure is now tied to growth-based metrics. OssDsign Catalyst remains highly competitive, and another scientific study published this quarter reinforced its unique properties as a standalone treatment in trauma. Each new publication strengthens our position and supports our efforts to expand surgeon awareness
Page 4
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 4 and adoption. We continue to invest in this growing evidence base and preparations for enrollment of first patients in our large, randomized controlled, Level 1 trial are proceeding according to plan. In summary, we have the right product and strategically we know the path forward. We are building the right team. We are expanding our evidence. All of this supports OssDsign’s goals of driving growth and solid business performance every quarter. Mark Waugh, CEO
Page 5
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 5 Statement of Operations OssDsign Catalyst – a state of the art nanosynthetic ™ bone graft Nearly 80% of Americans experience low back pain at some point in their lives and more than 1.5 million undergo spinal surgery each year, of which approximately half will need fusion surgery. Today approximately 20% of these surgeries are unsuccessful due to the lack of proper fusion (non-union). Bone graft plays a crucial role in the surgery to stimulate bone growth. The major advances provided by orthobiologic products are resulting in a shift in spinal surgery, as the use of synthetic bone graft substitutes has become more common to avoid the need to utilise allograft or iliac crest autograft. Traditional synthetic materials share similarities with bone tissue at a macro level, rather than on a nano level, leading to a less effective bone formation response. OssDsign Catalyst is a latest-generation state of the art nanosynthetic™ bone graft composed of a proprietary nano-crystalline silicate calcium phosphate. Being similar to the body’s own bone mineral architecture, OssDsign Catalyst provides a favorable bone biology environment for rapid and reliable bone formation. Clear commercial advantages OssDsign Catalyst is a high gross margin product with great scalability and large potential in the market for standard procedures, enabling extensive growth. OssDsign Catalyst received FDA clearance in 2020 and has been very well received in the U.S. market since its launch in August 2021. By the end of June 2026, more than 15,000 patients had been treated with OssDsign Catalyst in the U.S. Improved patient outcomes OssDsign Catalyst received FDA clearance in 2020 based on preclinical results from the most established and demanding non- clinical model for spinal fusion – the Boden model. OssDsign Catalyst surpasses results typically seen with other synthetic bone grafts used in this model. OssDsign is a developer and provider of next generation orthobiologic products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities, giving patients back the life they deserve. This has also been confirmed in the clinical study TOP FUSION where top-line results show a 93% spinal fusion rate at 12 months after surgery and 100% at 24 months after surgery with the novel nanosynthetic™ bone graft. All scores used to quantify pain, function and overall health in patients showed improvement in quality of life over time and no device-related adverse events were observed during the study. This is also in line with the first post-market safety report that was published in November 2022, which did not record any device-related complaints or adverse events. The data indicates that the use of OssDsign Catalyst leads to consistent and rapid bone healing and remodeling, with improved patient outcomes as a result. Altogether, OssDsign Catalyst has the proven potential to improve the success rates of spinal surgeries – a much-welcomed development for the millions of patients who require a spinal fusion to regain an active and healthy life. Subsequently, the positive findings outlined here have been further corroborated by additional preclinical research, published in the Journal of Orthopaedic Surgery and Research, as well as clinically, from the first 108 patient readout from our PROPEL registry, showing an 88.4% fusion rate in a highly complex patient cohort. USD 1.8 billion The U.S. market value for orthobiologics in spinal surgeries.
Page 6
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 6 Development of profit and financial position SECOND QUARTER Sales and Gross margin The OssDsign Group net sales for the second quarter of 2026 amounted to TSEK 37,776 (46,522), which translates to a flat growth quarter-over-quarter with constant exchange rates, or +2.4% growth in reported figures. Compared to the second quarter of 2025, this translates to a decrease of 16% with constant exchange rates, or 19% in reported figures, bearing in mind that nearly half of that decrease was due to the Q2 2025 numbers being inflated by last day orders. The current sales growth is in accordance with expectations and in line with our market guidance. Gross margin of 92.1% is an improvement over the 91.6% in the first quarter of 2026 but below the 96.8% in the second quarter of the previous year. The combined product and customer mix effects impacted the margin negatively in the quarter, albeit to varying degrees, with only minor effects from the USD/SEK exchange rate development. Operating result The operating result for the period April - June 2026 amounted to TSEK -12,348 (-6,936). Adjusted operating result for the same period amounted to TSEK -11,975 (-6,203), with the reduction in sales variable costs making up for some of the gross profit shortfall. Non- sales variable costs were in line with the corresponding quarter in the previous year, as well as with the first quarter in 2026. The effects of exchange rate changes at the EBIT level were marginal, due to the nature of our cost base, with the positive impact on operating expenses offsetting the negative impact on sales and COGS. Sales variable costs were considerably lower than in the previous year, being down to 44.8% (48.6%) of net sales in the period. Cash flow, investments and financial position Cash at the beginning of the period amounted to TSEK 170,484 and at the end of the period TSEK 152,531. Cash flow from operating activities of TSEK –11,811 (-11,895) was level with the same period in the previous year, entirely due to the positive working capital development. The positive working capital development was largely driven by the lower sales, but with considerably less impact from inventory and receivables than in Q1 2026. Cash flow from investments of TSEK -6,148 (-1,927) was level with the first quarter in 2026 and higher than the second quarter in 2025, driven entirely by investments in new product development, as per our communicated strategic plan. Total cash flow for the period was TSEK -18,084 (135,528), with the comparison period being distorted by the 2025 equity raise. There were no investments in tangible fixed assets in the period whereas new product development costs were capitalized to the amount of TSEK 6,148 (1,927) in intangible assets in the period. FIRST HALF YEAR Sales and Gross margin The OssDsign Group net sales for the first half year of 2026 amounted to TSEK 74,655 (91,016), which translates to a decrease of 10% compared to the first half year of 2025 with constant exchange rates, or 18% in reported numbers. The significant divergence in growth rates is entirely attributable to the exchange rate depreciation of the USD relative to the SEK, from 10.2 to 9.2, during the comparison periods. Gross margin of 91.9% for the the first half year of 2026 remains below the 96.6% in the corresponding period 2025. The margin was negatively affected by unfavourable product and customer mix. Operating result The operating result for the period January - June 2026 amounted to TSEK -25,813 (-19,633), with the comparison period affected by L TIP related costs for the 2024-28 program. The adjusted operating result for the same period amounted to TSEK -25,363 (-11,766), as a direct consequence of the lower sales and gross margin. The lower level of operating expenses, particularly sales variable costs, went some way to mitigate the gross profit deviation. The effects of exchange rate changes at the EBIT level were marginal, due to the nature of our cost base, with the positive impact on operating expenses offsetting the negative impact on sales and COGS. Sales variable costs were lower than in the previous year, being down to 45.9% (49.0%) of net sales in the period. Cash flow, investments and financial position Cash at the beginning of the period amounted to TSEK 100,858 and at the end of the period TSEK 152,531. Cash flow from operating activities amounted to TSEK -26,677 (-37,769), primarily due to the favourable working capital development in the first half of 2026, but also to the comparison period being more heavily impacted by L TIP/warrant related costs.
Page 7
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 7 Cash flow from investments of TSEK -12,160 (-3,231) was significantly higher than in the previous year, driven predominantly by investments in new product development, as per our communicated strategic plan. Total cash flow for the period was TSEK -39,122 (112,854), with the significant variance being driven by the directed share issue in the comparison period. There were no investments in tangible fixed assets in the period, with TSEK -448 of production related investments in the comparison period. New product development costs were capitalized to the amount of TSEK 12,160 (-2,784) in intangible assets in the period. SIGNIFICANT EVENTS DURING THE SECOND QUARTER OssDsign Catalyst® outperforms earlier-generation bone graft as a standalone treatment in trauma study On June 3, OssDsign announced the publication of a new scientific article in The Journal of Bone and Mineral Research (JBMR). The preclinical study evaluated OssDsign Catalyst as a standalone bone graft in trauma, comparing it to an earlier-generation bone graft. The results show significantly more bone formation with OssDsign Catalyst at earlier timepoints, as well as clear evidence that the graft is naturally broken down and replaced by the body over time – reinforcing the superiority of fourth-generation synthetic bone grafts like OssDsign Catalyst. OssDsign appoints Adam McCollister as new Vice President of Sales On June 25, OssDsign announced that Adam McCollister has joined the company as Vice President of Sales. Mr. McCollister will lead the Company’s U.S. sales strategy and execution, with a focus on accelerating adoption of OssDsign’s Catalyst nanosynthetic™ bone graft. SIGNIFICANT EVENTS AFTER THE END OF THE SECOND QUARTER There were no significant events after the end of the second quarter.
Page 8
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 8 Owners Number of shares Share Capital, % Försäkringsaktiebolaget Avanza Pension 13 472 151 12.2% Linc AB 11 104 396 10.0% TAMT AB 9 080 000 8.2% FSG Fund 8 000 000 7.2% SIX SIS AG, W8IMY 5 567 170 5.0% La Financière de l’Echiquier - LFDE 4 629 084 4.2% Nordea Livförsäkring Sverige AB 4 021 874 3.6% Protean Funds 3 786 211 3.4% AGB KRONOLUND AKTIEBOLAG 3 000 000 2.7% OLAUSSON THOMAS 2 403 732 2.2% Other shareholders 45 561 295 41.2% Total 110 625 913 100.00% OTHER DISCLOSURES Ownership structure Group structure OssDsign AB is the parent company of the Group which, in addition to OssDsign AB, consists of the wholly owned subsidiaries OssDsign Ltd with its registered office in England, OssDsign USA Inc with its registered office in Maryland, USA, and Sirakoss Ltd with its registered office in Scotland. OssDsign’s operations are mainly conducted through the parent company OssDsign AB, based in Uppsala, with the sales activities being conducted solely through OssDsign USA Inc. Employees At the end of the period, there were a total of 41 (33) employees, of whom 34% were women. This includes employees in Sweden, the U.K. and the U.S. Financing The Board regularly reviews the company’s existing and forecasted cash flows to ensure that the company has the funds and resources required to conduct the business and the strategic direction decided by the Board. The company’s long-term cash requirements are largely determined by how successful current and future products will be on the market. In order to satisfy requirements in the medium to long term, the company raised SEK 158 million in gross proceeds through a directed share issue in 2025. As of June 30, 2026, the group’s cash and cash equivalents amounted to SEK 152.5 million. The board deems the current liquidity to be sufficient for at least the next twelve months. Based on the sales development of the company’s products the board has confidence in the company’s mid- to long-term ability to become profitable and cash flow positive. Transactions with related parties The subsidiaries OssDsign USA Inc, OssDsign Ltd and Sirakoss Ltd invoice their costs to the parent company in accordance with transfer pricing agreements. As of the closing date, the Parent Company has a net claim on OssDsign USA Inc of TSEK 8,716 and a liability to Sirakoss Ltd of TSEK 3,032. Risks and uncertainties OssDsign risks and uncertainties include, but are not limited to, financial risks such as future financing, foreign exchange and credit risks. In addition to market risks, there are risks related to OssDsign operations, such as obtaining the necessary government licenses, product development, patents and intellectually property rights, product liability and forward-looking information that may affect the Company. In addition, developments in recent years have also introduced war, inflation, energy cost increases, interest rate risks, trade barriers and global instability to the agenda, all of which may come to affect access to raw materials, distribution, cost of goods and services, as well as customer demand and access to capital. Further information regarding the Company’s risk exposure can be found on pages 36-37 and 78-81 of the OssDsign Annual Report 2025. The direction towards protectionism expressed by the U.S. administration can conceivably affect OssDsign’s operations going forward. The US import tariffs, as communicated to date, however, are not deemed to have any material impact on the Group’s future earnings or financial position. Parent company In the second quarter of 2026, the parent company’s Net sales amounted to TSEK 5,925 (6,103). As all end customer sales are made from OssDsign USA Inc, the parent company sales are entirely intra-group. The parent company’s EBIT for the second quarter 2026 amounted to TSEK -24,917 (-10,927). At the end of the period, there were a total of 3 (4) employees in the parent company, of whom 67% were women. This includes only employees in Sweden.
Page 9
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 9 Condensed consolidated statement of comprehensive income 2026 2025 2026 2025 2025 SEK 000’ Apr 1 – Jun 30 Apr 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Dec 31 Profit/loss for the period -11 408 -8 341 -22 882 -22 918 -50 988 Items that will be reclassified subsequently to profit or loss 296 -705 528 -1 974 -17 379 Other comprehensive income for the period 296 -705 528 -1 974 -17 379 TOTAL COMPREHENSIVE INCOME FOR THE YEAR -11 112 -9 046 -22 354 -24 892 -68 367 2026 2025 2026 2025 2025 SEK 000’ Apr 1 – Jun 30 Apr 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Dec 31 Net sales 37 776 46 522 74 655 91 016 180 159 Cost of sales -2 967 -1 476 -6 071 -3 095 -6 691 Gross profit 34 809 45 046 68 584 87 921 173 468 Sales commissions and fees -16 931 -22 627 -34 295 -44 569 -87 484 Selling expenses -15 043 -11 427 -29 536 -23 184 -47 874 R&D expenses -2 962 -5 686 -7 131 -11 539 -20 118 Administrative expenses -11 747 -12 304 -22 819 -28 449 -66 350 Other operating income – 63 – 186 1 603 Other operating expense -473 – -616 – – Operating result -12 348 -6 937 -25 813 -19 634 -46 757 Net financial items 1 602 -949 3 510 -2 925 -3 397 Result before income tax -10 746 -7 886 -22 303 -22 559 -50 154 Income tax -662 -455 -579 -359 -835 RESUL T FOR THE PERIOD -11 408 -8 341 -22 882 -22 918 -50 988 Condensed consolidated income statement
Page 10
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 10 Condensed consolidated balance sheet 2026 2025 2025 SEK 000’ June 30 June 30 Dec 31 ASSETS Fixed assets Intangible assets 160 803 162 309 150 029 Tangible fixed assets 1 437 2 355 1 906 Financial assets 2 573 136 132 Total fixed assets 164 813 164 799 152 067 Current assets Inventories 21 285 17 964 22 678 Accounts receivable 22 040 27 158 26 131 Tax receivable – 581 – Other receivables 819 674 590 Prepayments 6 196 4 041 5 061 Cash and cash equivalents 152 531 212 739 191 346 Total current assets 202 870 263 158 245 806 TOTAL ASSETS 367 683 427 957 397 873 2026 2025 2025 SEK 000’ June 30 June 30 Dec 31 SHAREHOLDER EQUITY AND LIABILITIES Equity 287 875 343 706 310 031 Total equity 287 875 343 706 310 031 Long-term liabilities Finance lease liabilities 1 927 403 Other liabilities 52 013 57 316 52 172 Total long-term liabilities 52 014 58 243 52 575 Current liabilities Accounts payable 9 595 6 590 5 327 Lease liabilities 934 982 969 Tax liability 9 – 48 Other current liabilities 470 382 10 002 Accrued expenses and deferred income 16 786 18 054 18 922 Total current liabilities 27 794 26 008 35 268 Total liabilities 79 808 84 251 87 843 TOTAL EQUITY AND LIABILITIES 367 683 427 957 397 873
Page 11
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 11 Condensed consolidated change in shareholder’s equity SEK 000’ Share Capital Other Capital Contributions Reserves Profit (loss) brought forward Total Equity Opening balance 2025-01-01 6 104 796 024 30 843 -618 909 214 061 Profit/loss for the period – – – -22 918 -22 918 Other comprehensive income – – -1 974 – -1 974 Total comprehensive income – – -1 974 -22 918 -24 892 Transactions with shareholders Warrant programmes – – – 4 980 4 980 New share issue 718 157 406 – – 158 124 Issue expenses – -8 569 – – -8 569 Total transactions with shareholders 718 148 837 – 4 980 154 535 CLOSING BALANCE 2025-06-30 6 822 944 861 28 869 -636 845 343 706 Opening balance 2026-01-01 6 914 954 366 13 464 -664 711 310 031 Profit/loss for the period – – – -22 882 -22 882 Other comprehensive income – – 528 – 528 Total comprehensive income – – 528 -22 882 -22 354 Transactions with shareholders Warrant programmes – – – 198 198 Total transactions with shareholders – – – 198 198 CLOSING BALANCE 2026-06-30 6 914 954 366 13 992 -687 395 287 875
Page 12
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 12 Condensed consolidated statement of cash flow 2026 2025 2026 2025 2025 SEK 000’ Apr 1 – Jun 30 Apr 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Dec 31 Operating activities Operating result -12 348 -6 937 -25 813 -19 634 -46 757 Non cash adjustment -1 414 947 -457 1 865 -788 Financial items 1 602 -949 3 510 -2 925 -3 397 Income taxes paid/received -659 -914 -764 -1 021 -1 393 -12 820 -7 853 -23 524 -21 716 -52 335 Changes in inventories 14 -2 313 1 792 -5 293 -10 182 Changes in receivables 158 -4 865 3 934 -5 491 -6 243 Changes in current liabilities 836 3 136 -8 879 -5 269 4 725 Total change in working capital 1 008 -4 042 -3 153 -16 054 -11 699 Cash flow from operating activities -11 811 -11 895 -26 677 -37 769 -64 034 Investment activities Proceeds and purchase of intangible assets, net -6 148 -1 927 -12 160 -2 784 -6 723 Proceeds and purchase of property, plant and equipment, net – – – -448 -677 Cash flow from investment activities -6 148 -1 927 -12 160 -3 231 -7 400 Financing activities New share issue – 158 125 – 158 125 168 086 Share issue costs – -8 569 – -8 569 -8 934 Warrants 121 121 198 4 980 5 185 Proceeds/repayments from borrowings, net – -86 – -214 -214 Repayment of lease liabilities -246 -242 -483 -469 -945 Cash flow from financing activities -125 149 349 -285 153 854 163 178 Cash flow for the period -18 084 135 528 -39 122 112 854 91 743 Cash and cash equivalents at the beginning of the period 170 484 100 858 191 346 100 858 100 858 Exchange rate adjustments – cash, cash equivalents and overdrafts 130 -276 307 -972 -1 255 CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 152 531 212 739 152 531 212 739 191 346
Page 13
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 13 Condensed income statement, parent company 2026 2025 2026 2025 2025 SEK 000’ Apr 1 – Jun 30 Apr 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Dec 31 Net sales 5 925 6 103 12 861 16 489 25 023 Cost of goods sold -3 463 -3 321 -7 419 -7 697 -11 389 Gross profit 2 462 2 783 5 442 8 792 13 633 Sales commissions and fees -17 -623 -420 -1 455 -2 695 Selling expenses -12 595 -206 -13 069 -331 -1 041 R&D expenses -7 573 -4 404 -15 603 -10 245 -20 357 Administrative expenses -7 816 -8 476 -15 235 -21 703 -47 812 Other operating income – – – – 1 353 Operating result -25 539 -10 927 -38 884 -24 942 -56 919 Net financial items 1 605 -947 3 516 -2 921 -3 390 Result before income tax -23 934 -11 873 -35 367 -27 862 -60 309 Income tax – – – – – RESUL T FOR THE PERIOD -23 934 -11 873 -35 367 -27 862 -60 309 Condensed consolidated statement of comprehensive income, parent company 2026 2025 2026 2025 2025 SEK 000’ Apr 1 – Jun 30 Apr 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Jun 30 Jan 1 – Dec 31 Profit/loss for the period -23 934 -11 873 -35 367 -27 862 -60 309 Items that will be reclassified subsequently to profit or loss – – – – – Other comprehensive income for the period – – – – – TOTAL COMPREHENSIVE INCOME FOR THE YEAR -23 934 -11 873 -35 367 -27 862 -60 309
Page 14
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 14 Condensed balance sheet, parent company 2026 2025 2025 SEK 000’ Jun 30 Jun 30 Dec 31 ASSETS Fixed assets Financial assets 137 687 137 687 137 687 Total fixed assets 137 687 137 687 137 687 Current assets Inventories 18 514 14 817 20 563 Intercompany receivables 23 442 15 173 14 032 Tax receivable 569 576 363 Other receivables 383 674 468 Prepayments 2 974 2 954 1 989 Cash and cash equivalents 143 285 205 815 182 351 Total current assets 189 167 240 009 219 765 TOTAL ASSETS 326 855 377 696 357 452 2026 2025 2025 SEK 000’ Jun 30 Jun 30 Dec 31 SHAREHOLDER EQUITY AND LIABILITIES Equity Equity 251 765 309 983 287 132 Total equity 251 765 309 983 287 132 Provisions Other provisions 50 072 54 701 50 072 Total provisions 50 072 54 701 50 072 Current liabilities Accounts payable 3 357 5 252 2 579 Intercompany liabilities 17 759 1 026 1 838 Other current liabilities 190 412 9 780 Accrued expenses and deferred income 3 713 6 321 6 052 Total current liabilities 25 018 13 012 20 249 Total liabilities 75 090 67 713 70 321 TOTAL EQUITY AND LIABILITIES 326 855 377 696 357 452
Page 15
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 15 Notes Note 1 | Accounting Principles This summary interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and applicable regulations in the Swedish Annual Accounts Act. The interim report for the Parent Company has been prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim Financial Reporting. The same accounting and valuation policies have been applied for the Group and the Parent Company as in the latest Annual Report. Disclosures in accordance with IAS 34.16A occur in the financial reports and the accompanying notes, and also in other parts of the interim report. An alternative performance measure, Adjusted operating result (EBIT), was added in 2025. Adjusted EBIT is defined as EBIT excluding LTIP and CEO transition related costs. Note 2 | Estimates and assessments Estimates and assessments are evaluated on an ongoing basis and are based on historical experience and other factors, including expectations of future events that are considered reasonable under prevailing conditions. There has been no change in the estimates and judgments made in the Annual Report for 2025. Note 3 | Information regarding operating segments The Group’s operations are divided into operating segments based on the parts of the business the Company’s highest executive decision-maker follows up, so called “management approach”. The Group’s internal reporting is based on the Group management following up the operation as a whole. Based on its internal reporting, the Group has identified that the Group has only one segment. Income from external customers has been attributed to individual countries from which the sales have taken place. As of January 1, 2024, the only country in which such sales are taking place is the USA and only within the product category Orthobiologics. The Group’s fixed assets are located to Sweden, the U.K. and the U.S. Note 4 | Equity The share capital of the Parent Company consists only of fully paid ordinary shares with a nominal (quota value) value of SEK 0.0625 / share. The company has 110 625 913 class A shares. Amounts received for issued shares in addition to the nominal value during the year (premium) are included in the item “Other contributed capital”, after deduction for registration and other similar fees and after deduction for attributable tax benefits. 2026 2025 Jan 1 – Jun 30 Jan 1 – Jun 30 Subscribed and paid shares At the beginning of the period 110 625 913 97 658 920 Directed share issue – 11 500 000 Shares from exercise of warrant program – – Subscribed and paid shares 110 625 913 109 158 920 Shares for share-based payments – – SUM AT THE END OF THE PERIOD 110 625 913 109 158 920 NET SALES BY GEOGRAPHIC MARKET Apr – Jun Jan – Jun Jan – Dec SEK 000’ 2026 2025 2026 2025 2025 USA 37 776 46 522 74 655 91 016 180 159 TOTAL 37 776 46 522 74 655 91 016 180 159 NET SALES BY PRODUCT CATEGORY Apr – Jun Jan – Jun Jan – Dec SEK 000’ 2026 2025 2026 2025 2025 Orthobiologics 37 776 46 522 74 655 91 016 180 159 TOTAL 37 776 46 522 74 655 91 016 180 159 Apr – Jun Jan – Jun Jan – Dec SEK 000’ 2026 2025 2026 2025 2025 EBIT -12 348 -6 936 -25 813 -19 633 -46 757 L TIP related costs 373 733 450 7 867 8 172 CEO transition costs – – – – 12 086 Adjusted EBIT -11 975 -6 203 -25 363 -11 766 -26 499 ADJUSTED OPERATING RESULT
Page 16
OSSDSIGN AB | info@ossdsign.com | ossdsign.com | 16 Signatures Financial calendar 2026 Interim Report Q3, 2026 November 3 Year-end Report, 2026 February 9, 2027 OSSDSIGN AB – UPPSALA, AUGUST 18, 2026 Tomas Blomquist Board member Per Aniansson Chairman of the Board Jill Schiaparelli Board member Mark Waugh CEO Christer Fåhraeus Board member The Board of Directors and the CEO provide their assurance that this interim report provides an accurate view of the operations, position and earning of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group. This report has been prepared in both a Swedish and an English version. In the event of any discrepancy between the two, the Swedish version shall apply. This report has not been audited. David Jern Board member
Page 17
17 | OSSDSIGN AB | info@ossdsign.com | ossdsign.com OssDsign AB, Ulls väg 29C, SE 756 51 Uppsala, Sweden info@ossdsign.com ossdsign.com CONTACT Mark Waugh, CEO +1 260-804-1342 mark.waugh@ossdsign.com Anders Svensson, CFO +46(0)70-272 96 40 anders.svensson@ossdsign.com